Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan
Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019.
Read moreChugai
EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of
Read more
Chugai Presents Results from Second Positive Global Phase III Clinical Study of Satralizumab in NMOSD at ECTRIMS 2019
Following a positive study where satralizumab was added to baseline therapy, satralizumab monotherapy significantly reduced risk of relapse by 55%
Read more